Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.42), $0.04 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $504 thousand versus the consensus estimate of $480 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.